Last reviewed · How we verify

NCT05201456: LVE

LithoVue Elite Registry

Withdrawn Last updated 18 December 2023
What this trial tests

trial testing LithoVue Elite System in Kidney Stone. Withdrawn.

Timeline
1 April 2023
Primary endpoint
1 April 2023
1 December 2023

Quick facts

Lead sponsorBoston Scientific Corporation
StatusWithdrawn
Study typeOBSERVATIONAL
Start date1 April 2023
Primary completion1 April 2023
Estimated completion1 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

Boston Scientific Corporation — full company profile →

Who can join

Eligibility, any sex, with Kidney Stone or Urolithiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To obtain postmarket safety and efficacy data on Boston Scientific LithoVue™ Elite System.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Single use flexible ureteroscopes: Current status and future directions.
    Juliebø-Jones P, Ventimiglia E, Somani BK, Æsøy MS, et al · · 2023 · cited 15× · PMID 37818020 · DOI 10.1002/bco2.265

Verify or expand the search:

Other recruiting trials for Kidney Stone

Currently open trials in the same condition.

Other Boston Scientific Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05201456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing